Vittorio Studiale
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Vittorio Studiale
Jul 1, 2024, 08:08 |
Blog
CtDNA in early Colorectal cancer
Vittorio Studiale, Medical Oncology resident at Pisan hospital-university, shared on X: "CtDNA in early CRC >…
Jun 28, 2024, 15:58 |
Insight
Updates on BOT/BAL from ESMOGI24
ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…
Jun 28, 2024, 13:09 |
Insight
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…
Jun 28, 2024, 08:19 |
Societies
15 Posts You Should Not Miss From The 1st Day of ESMOGI24
ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29…
Jun 26, 2024, 12:19 |
Societies
Brilliant keynote lecture on KRAS inhibitors by Dr. Ryan Corcoran at ESMOGI24
Vittorio Studiale, Medical Oncology resident at AOUP, shared on X: "European Championship of gastrointestinal oncology?…
All:
5
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube